OSUR

Over the past six months, OraSure Technologies (OSUR) stock has gained 27.45% and 60.49% year-to-date. Key events include the announcement of Q2 2026 financial results on August 5, 2026, which beat consensus expectations for EPS and revenue, with core revenue flat year-over-year and the company swinging to a Q2 profit. On July 21, 2026, OraSure received Emergency Use Authorization for a second-generation Ebola test. In June 2026, the company received FDA clearance for the Colli-Pee at-home urine collection device for sexually transmitted infections. A new investor group, led by Islet Management and Yorkville-affiliated funds, reported beneficial ownership of approximately 6.4% of OraSure's outstanding common stock on September 17, 2026, potentially seeking board seats and a possible sale. The stock moved higher on October 8, 2026, possibly due to technical factors and activist investor pressure. The third-quarter report is expected in early November 2026.